Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complication
- 15 November 1994
- Vol. 74 (10), 2850-2856
- https://doi.org/10.1002/1097-0142(19941115)74:10<2850::aid-cncr2820741018>3.0.co;2-t
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Interferon-α and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trialsCancer, 1993
- Inpatient continuous-infusion interleukin-2 in 788 patients with cancer the national biotherapy study group experienceCancer, 1993
- A Phase II Trial of Concomitant Human Interleukin-2 and Interferon-??-2a in Patients with Disseminated Malignant MelanomaJournal of Immunotherapy, 1993
- Reversible Cardiomyopathy After High-Dose Interleukin-2 TherapyJournal of Immunotherapy, 1992
- Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression TrialThe American Journal of Cardiology, 1991
- Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancerCancer, 1990
- Complete heart block due to interleukin-2 therapyAmerican Heart Journal, 1990
- Reversible Cardiac Dysfunction Associated with Interferon Alfa Therapy in AIDS Patients with Kaposi's SarcomaNew England Journal of Medicine, 1989
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987